Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
some lite reading for a Sunday
https://www.fiercepharma.com/sales-and-marketing/purdue-loses-a-battle-war-against-oxycontin-generics#:~:text=It%27s%20bad%20news%20for%20Purdue%20Pharma%20but%20good,to%20cheap%20knockoff%20versions%20of%20the%20blockbuster%20med.
Another spin on the Purdue patent loss
It's bad news for Purdue Pharma but good news for generics makers such as Teva Pharmaceutical Industries ($TEVA). A federal appeals court affirmed a lower court's decision to toss out some Purdue patents for its top-selling pain drug OxyContin, further opening the door to cheap knockoff versions of the blockbuster med.
I think part of elites issue is that Nasrat says things that in my opinion take too long to materialize.
Hi emperor.
Sorry for your ban. You brought to us a lot and made possible the win against the shorts. Your understanding of elite made it possible to win the guessing contest and become our true leader for a quarter. Hope to see you soon with us again.
How much $$ we talkin’
Cake for a better I-hub experience put all non shareholders on ignore. Easy to tell who is who.
GLTY
Fidelity is having fraud issues...it's been well discussed on reddit. It's causing some accounts to have long settling periods. But not all.
I’m fidelity, just had a trade/sell and checked a new box to have the funds directly trf to my other bank. Happened within the 3 day period?
YES
&
YES !!!!!!!!!!!!
Flick The Tick ...................
Repeal The Mikah tax !!!!!!!!!!!!!
IB_🤴🏻
That's My Opinion
We should focus on MIKAH and what this means to a potential buyout. Does Nasrat get paid twice
That’s crazy. I figured there would be a T+2 settlement wait period, but that’s like 2 weeks.
I had a problem with them. I wrote a letter to their ceo, their support, finra and the sec.
This is not normal practice
Only thing confusing is your post. Why are you so focused on this today? Are you worried that the short position you are working to cover is in trouble. Seems that way.
I love talking about Mikah. It's only one product and it's the blood flowing through Elites R&D veins right now.
I’m sure that Nasrat , oh wait, I mean Elite, could not buy out Sungen. Lucky that Elite, oh no wait, I mean Nasrat,had the money to buy out sungen. Wonder if there a legal reason that seeing that Nasrat had the money, he couldn’t just loan the money to Nasat, oh no wait, I mean Elite.
It’s so confusing
Excellent questions. I wonder if MIKAH makes all of this messy. Just not sure
Here is the question on Oxy I have been thinking about. Elite was sued over patent infringement by Purdue. This was expected obviously as Purdue is trying to hold on by their fingernails at this point and that battle is about over as the verdicts and appeal verdicts come in....
So, if Elite is being sued for patent infringement and that patent and associated patents have been ruled invalid (see the verdict released last week in the Accord trial),
Isn't the trial case basically over? There is a stay Pending that outcome (which has been completed in Elite's favor) so what is next?
Can really only be three things
1- Elite and Purdue make a deal and they have this stay based on the outcome which was ruled in Elites favor. So Purdues best chance to get something out of this to make a deal and license it to Elite for some predetermined period of time
2- Elite files motion to dismiss since there is no grounds as patent is invalid. Pdufa date is in a few weeks and Elite already did all the extra studies that were needed.
3-Purdue tries another angle but I'm not sure what else there is. The patent invalidated seems to be the entire piece. It's the hard shell aspect of the pill and is found to be "obvious". The rest is just Oxycontin generic...
I think all of us shareholders should demand that Nasrat provide more transparency around MIKAH.
What drugs are pending launch? One is due here pretty soon. Couple weeks. Can you tell us what the CEO noted about these drug launches. How many weeks are they spaced out?
Can you tell us what they are?
Bet you aren't allowed. Lol
Yes. Elite would benefit greatly from the CEO following up on his public commitments / comments
I wonder why MIKAH still continues to be a concern for investors. Why doesn’t Elite just consolidate and eliminate this concern. Seems wrong that MIKAH swooped in here and bought cheap ( I think). Did elite have insight into what a great investment this would be ? Just my opinion
FIDELITY TRADING, CANT BELIEVE AFTER SETTLEMENT FIDELITY IS NOT ALLOWING YOU TO WITHDRAW CASH BUT THE WILL LET YOU BUY MORE STOCK,I SOLD STOCK SHARES ON SEPTEMBER 17 AND WONT BE ALLOWED TO WITHDRAW CASH UNTIL OCTOBER 3, FIDELITY BROKERAGE ANYONE HAVING THE SAME BS
You don't even know what you are saying. It's funny but sad. You aren't happy that the Chinese company (who could no longer support it due to financial issues) doesn't own the profit split on one product with Elite and Mikah has it now with the exact same terms? I sure am. You guys are proving the opposite.
By the way, the best part of this deal is it will make life much easier when the company is sold which you also know is going to happen.
Boring
Come on tell us. What market maker you work for?
In the "fundimentals" is there a line item for the CEO's private (parasitic) company.??....nope
Mikah is none of your Business, per the Rat.
That is not very "fundamental"
Investors will never...NEVER. know how much
Mikah is fleecing Elite.
I challenge any one on this MB to come up with
A dollar amount, you cant
Yes. That’s where you’ll also get sell-side analyst coverage at real investment firms beyond the Zack’s coverage we have today. A couple of analysts can go a long way in getting exposure to investment community, plus passive funds (majority of investment funds today) can buy in once on NASDAQ.
He was pretty close the last time he made a statement like that. Don’t recall many Monday press releases though. We will see
Literally...if pumping is saying the revenue has been and is going to continue to be exponential. And everyone here knows this even the market maker stooge.
Lol. No one is pumping. If pumping means talking about numerous drug launches pending, drugs pending approval with PDUFA dates in the next few weeks, drugs trials pending announcement evidenced by conf calls and large increases in R&D spending...?
What would you like to talk about?
How many shares the market maker you work for is short? Evidenced by your 10 years here and only here trying to convince people the sky isn't blue and water isnt wet?
Do you ever wonder if you caused people pain and discouraged them from buying a stock that everyone knows is going up over the next year for one simple reason? Exponential growth in revenue and pipeline?
Does it bother you at all that this is your job?
All a pumper has to say is “Look at the fundamentals”. There’s no denying the reality!
"Could be"......right from the pumpers script.
If, should, gonna, could be, next cc, get ready,
Take these away and pumpers can't post. Lol
At what point do we get the company of large funds being allowed to partake in the festivities…. Do we have to uplist for them to have access to
You said same thing at 2¢, lol
This proves your post is BS
Upcoming ELTP Catalysts:
UPDATE :
Going right down the line !!!!
X 1. Cash Flow Positive - 5 years
X 2. Purchase building housing their cGMP registered facility for research, development, manufacturing and packaging of pharmaceutical products.
X 3. Adderall IR $335 Million IMS market Approved and Launched
X 4. Adderall XR $1.56 Billion IMS market Approved and Launched
X 5. Double digit quarterly revenues in millions
X 6. Create in house marketing and distribution: Kirko Kirkov, Doug Plassche and their teams
X 7. Prasco/Burel Adderall agreement - January 1st 2024
X 8. First shipment Adderall XR to Prasco/Burel Dec 2023
X 9. DEA increases manufacturing quotas for Adderall & Vyvance
X 10. Generic OxyContin - FIRST TO FILE FDA Aug 17, 2023 $720 Million
X 11. Generic Vyvanse - $5.1 BILLION - FDA submission Dec 2023
X 12. FDA Acceptance of Generic OxyContin Sept 2023
X 13. Lease additional manufacturing space and storage vault for new Needle Mover ANDAs - Jan 2024
__14. Dopamine Agonist Approval (probably Requip XL or Mirapex ER). $12 Million
__15. Obtain Full ownership of Adderall IR $ 335 Million from MIKAH
__16. Obtain Full ownership of Adderall XR $ 1.56 Billion from MIKAH
X 17. Vigabatrin Approval $233 Million
X 18. Pyros Vigabatrin -settle VigPoder trade mark challenge and LAUNCH
X 19. Generic Methotrexate Antimetabolite- Approval
X 20. Launch generic Methotrexate $63.4 Million
X 21. $50+ million in yearly revenues
X 22. Lowest PE ratio for OTC Healthcare sector
X 23. Become the ONLY company showing rapid growth on the OTC while being profitable
X 24. Put Opioids back on the Table- due to reduced risk of opioid litigation
X 25. Receive Analyst Coverage - Upgrade to Market Outperform - Zacks Investment Research
__26. Generate revenues over $20 million/quarter
__27. Final Approval of New Manufacturing Facility/Expansion
__28. Double output of manufacturing and packaging facilities
__29. Launch approved generic Tylenol with Codeine $45 Million
__30. Launch approved generic Norco - hydrocodone acetaminophen IMS $477 Million
__31. Launch approved generic Percocet - oxycodone acetaminophen IMS $500 Million
__32. Launch approved generic Dolophine - methadone HCL tablets IMS $30 Million
__33. Generic Vyvanse Approval and Launch
__34. Generic Concerta- FDA submission $1.2 BILLION
__35. $100 million in yearly revenue
__36. Generic OxyContin Tentative Approval $720 Million
__37. Elite prevail over Purdue in Generic OxyContin infringement suit - second 6 month stay - active Accord/Purdue suit causing delay
__38.Launch generic OxyContin $720 Million
__39. Resume R&D on SequestOx Abuse Deterrent Oxycodone
__40. European distribution - Dexcel partnership approval by Israeli Health
__41. $200 million in yearly revenue
__42. Patented Unique ADF (w/o naltrexone) drug C in SequestOx reformulation trial
__43. Undisclosed Mikah ANDA(s)
__44. Undisclosed ANDAs/NDAs
__45. Generic Concerta Approval and Launch
__46. DollarLand PPS
__47. Big Pharma bid
__48. UpList to the NASDAQ Exchange
__49. ELTP Elite Pharmaceutical Buyout - 2 1/2 years or less from Feb 2024
Bullish
My apologies. Ai has its pros and cons.
Elites OxyContin could be approved in 2 weeks.
Accord needs to get goin’
HammerTime
My own concerns are over the limited time I have for other smaller holdings to rip for transferring here before Novembers possible runs to start… none the less we’re in for some grand experiences, ‘tis the season friends
I’m not so sure of that.
The research that I found says that WES Pharma Inc. is primarily focused on developing and manufacturing its “own” generic and specialty pharmaceutical products rather than manufacturing drugs for other companies. The company's business model revolves around developing complex generic and innovative specialty pharmaceutical products in oral solid and liquid forms
Note: the information in this post was generated with A.I.(Accurate Information)
http://www.wespharma.com/about-wes.html
There's like 5 drugs launches coming short term, an approval, maybe another approval, a drug trial, news on Oxy, record earnings for the quarter...
Those products are about $8 billion dollars.
You guys need shares. And you are boring at this point.
I just hope we get good news about oxy in the coming days or weeks. Just any good news would benefit ELTP.
I think the worst thing is the BS around the safe harbor act. Companies , elite, should not be able to use this at the start of a CC. My opinion
Not hard to answer...
Flippers and traders pretending to be longs, pump this up and suck in new investors. The 2 most prominent cheer leaders are the biggest flippers on this MB. Then they sell,
Age old strategy, nothing complex.
A few fake longs with multiple IID's working together.
What worries me is elite comes out with a great CC filled with forward looking statements. Needle movers and all. Stock jumps yet now meaningful news so we just drift down.
It’s not approved yet, that wasn’t the point.
I don’t see OxyContin in Orange book for Accord ?
Intas Pharmaceuticals does not appear to have any manufacturing facilities in the United States.
Intas operates 14 manufacturing facilities in total, with 11 located in India and the rest in the UK and Mexico.
Specifically, Intas has 9 formulation manufacturing facilities in India, and others in the U.K. and Mexico.
The company's manufacturing sites are listed as being in India (5 locations), UK (2 locations), and Mexico (1 location).
Accord Healthcare, a subsidiary of Intas, has three US FDA approved facilities, but these are all based in India - two in Ahmedabad ("Matoda" and "SEZ") and one in Dehradun.
Wonder if this will play a role with generic Oxy? 🤷♂️ Time will tell
THX, I hope it works
Followers
|
1000
|
Posters
|
|
Posts (Today)
|
4
|
Posts (Total)
|
409426
|
Created
|
03/24/09
|
Type
|
Free
|
Moderators jimr1717 mrwrn2010 NASDAQ2020 IB_ namtae Dr JoeBarducci |
Senior Moderator: IB_
Posted: 7/02/2024
________________________________________________________________________________________________________________
Elite Pharmaceuticals, Inc. |
Website | Location | Employees | Facility | CEO |
www.elitepharma.com | Northvale, New Jersey | 64 | 85,000 sq ft | Nasrat Hakim |
Products & Pipeline | ||||
Drug | Market Size | Status | Competitors | Marketed By |
Adderall IR | 389.8 M | On Market | 15 | Elite |
Adderall XR | 1.56 B | On Market | 10 | Elite & Prasco |
Dantrolene | 6.3 M | On Market | 2 | Elite |
Isradipine | 5.5 M | On Market | 1 | Elite |
Loxapine | 5 M | On Market | 2 | Elite |
Phendimetrazine | 4.5 M | On Market | 4 | Elite |
Trimipramine | 2 M | On Market | 1 | Elite |
Naltrexone | 16 M | On Market | 5 | Precision Dose |
Phentermine Capsules | 7.5 M | On Market | 6 | Precision Dose |
Phentermine Tablets | 40 M | On Market | 8 | Precision Dose |
Vigabatrin | 233.7 M | On Market | 13 | Pyros |
Doxycycline | 85 M | Approved (Discontinued) | 9 | ---------- |
Tylenol with Codeine | 45 M | Approved in Launch Queue | 5 | ---------- |
Dopamine Agonist | 12 M | Filed with FDA - 22 Dec 2022 | ---------- | ---------- |
Methotrexate | 63.4M | On Market | 8 | Elite |
Percocet | 500 M | Approved in Launch Queue | 14 | ---------- |
Norco | 477 M | Approved in Launch Queue | 12 | ---------- |
Methadone | 30 M | Approved in Launch Queue | 8 | ---------- |
OxyContin | 720 M | Filed with FDA - 17 Aug 2023 | ??? | ---------- |
Vyvanse | 5.10 B | Filed with FDA - 21 Dec 2023 | 11 | ---------- |
Concerta | 1.16 B | In Development (Final Stages) | 8 | ---------- |
Financials | ||||
Fiscal Year | Revenue | Change | Net Income | Change |
2019 | 7,568,508 | ---------- | (9,279,321) | ---------- |
2020 | 17,994,639 | +137.76% | (2,240,351) | +75.86% |
2021 | 25,380,749 | +41.05% | 5,088,421 | +327.13% |
2022 | 32,262,117 | +27.11% | 8,898,245 | +74.87% |
2023 | 34,155,114 | +5.87% | 3,561,846 | -59.97% |
2024 | 56,625,128 | +65.79% | 20,108,631 | +464.56% |
2025 Q-1 | 18,803,063 | +109.39% | 3,864,056 | +144.00% |
2025 Q-2 | ||||
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |